Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Not Applicable

Recruiting

• Conditions: Nasopharyngeal Cancer; Epstein-Barr Virus Related Carcinoma
• Interventions: Radiation: FDG-PET; Radiation: Galium-68 DOTATATE

• Registration Number: NCT05581550
• Lead Sponsor: National Cancer Centre, Singapore

Brief Summary

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-06-29
• Study First Submitted: 2021-12-09
• Study First Submitted QC: 2022-10-13
• Study First Posted: 2022-10-14
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-20
• Last Update Posted: 2024-05-21
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
• Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
• Histologically confirmed NPC
• Above 21 years of age

Exclusion Criteria

• Patients below 21 years of age
• Pregnant and breast feeding ladies

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
PET imaging	FDG-PET	-
PET imaging	Galium-68 DOTATATE	-

Primary Outcome Measures

Name	Time	Method
Amount of tracer uptake in the tumour lesions of NPC patients	From time of tracer injection to time the scan is performed	The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.

Secondary Outcome Measures

Name	Time	Method
Number of somatostatin receptors in patient biopsy samples	Upon signing the informed consent form
Amount of tracer uptake in the tumour lesions of patients with EBV related cancers	From time of tracer injection to time the scan is performed	The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.
Amount of somatostatin circulating tumour cells in patient blood samples	At the time of scan

Trial Locations

Locations (1)

National Cancer Centre Singapore; 🇸🇬 Singapore, Singapore